Management of Methicillin-Sensitive Staphylococcus aureus (MSSA) Bacteremia

Definition and Diagnosis

The Infectious Diseases Society of America defines MSSA bacteremia as the presence of methicillin-susceptible Staphylococcus aureus in the bloodstream, confirmed through positive blood cultures 1
Rapid multiplex polymerase chain reaction (rmPCR) testing can accurately identify S. aureus and determine methicillin susceptibility directly from positive blood culture bottles, allowing for faster diagnosis and appropriate treatment 1

Clinical Presentation and Evaluation

Patients with MSSA bacteremia require a thorough evaluation including repeat blood cultures to document clearance of bacteremia, echocardiography to evaluate for infective endocarditis, and clinical assessment to identify the source and extent of infection 1, 2, 3
Risk stratification is recommended to guide further workup, with low-risk patients having hospital-acquired bacteremia, blood cultures clear in <48 hours, no persistent fever, and timely antibiotic start, while high-risk patients have risk factors for endocarditis, implanted prostheses, history of injection drug use, and blood cultures positive >48 hours 1

Treatment

The American College of Physicians recommends antistaphylococcal beta-lactams as the preferred first-line treatment for MSSA bacteremia, with options including nafcillin or oxacillin 2g IV every 6 hours, and cefazolin 1-2g IV every 8 hours as an effective alternative 2, 4
For patients with severe beta-lactam allergies, vancomycin 15-20 mg/kg IV every 8-12 hours is recommended 2

Duration of Therapy

The Infectious Diseases Society of America recommends a minimum of 2 weeks of therapy for uncomplicated bacteremia, 4-6 weeks for complicated bacteremia, and 6 weeks for infective endocarditis 2, 3

Monitoring and Follow-up

Follow-up blood cultures should be obtained 2-4 days after initial positive cultures to document clearance of bacteremia, and persistent bacteremia (>48-72 hours) is a poor prognostic sign that should prompt additional investigation for metastatic foci of infection 1, 2, 3

Complications and Special Considerations

MSSA bacteremia can lead to metastatic infections including infective endocarditis, osteomyelitis, septic arthritis, and deep tissue abscesses, and source control is critical for successful treatment 1, 3
The American Heart Association recommends surgical debridement and drainage of associated soft-tissue abscesses, and removal of infected intravascular devices 1, 3

Prognosis

Early appropriate antibiotic therapy and source control are the most important factors in improving outcomes for patients with MSSA bacteremia 2

Treatment of MSSA Bacteremia with Flucloxacillin

First-Line Treatment Options for MSSA Bacteremia

Flucloxacillin (2g IV every 6 hours) is considered equivalent to other antistaphylococcal penicillins like nafcillin and oxacillin for treating MSSA bacteremia, as recommended by the European Society of Cardiology 5

Clinical Considerations

For MSSA bacteremia with brain abscess or CNS involvement, flucloxacillin is preferred over cefazolin due to better blood-brain barrier penetration, according to the American Heart Association 6
Gentamicin should not be added to flucloxacillin therapy as it increases nephrotoxicity without improving clinical outcomes, as stated by the American Heart Association 6
The duration of therapy for infective endocarditis is 6 weeks, as recommended by the American Heart Association 7

Potential Pitfalls

Empiric vancomycin should be switched to flucloxacillin once MSSA is confirmed, as beta-lactams have superior outcomes for MSSA infections, according to the Infectious Diseases Society of America 8

Management of MSSA Bacteremia

Introduction to Management

The Infectious Diseases Society of America (IDSA) recommends early drainage of purulent material for optimal therapy in patients with MSSA infections and fluctuant collections (strong, high evidence) 9
Surgical drainage of the fluctuant area is urgently needed, even though CT is negative for abscess, as clinical signs of fluctuance suggest a drainable collection 10, 11

Diagnostic Approach

The patient should undergo repeat blood cultures to document clearance or persistence of bacteremia 12, 13
Consider MRI of the affected area if surgical exploration does not reveal a drainable collection, as MRI is more sensitive than CT for detecting soft tissue infections and pyomyositis 9, 10
Persistent bacteremia should prompt evaluation for endocarditis with echocardiography, as recommended by the European Society of Cardiology 12, 14

Management Recommendations

The IDSA guidelines strongly emphasize that "in most cases of abscess, drainage is critical for optimal therapy" 10
Early source control is a key evidence-based practice in the treatment of S. aureus bacteremia, and should be prioritized over antibiotic therapy alone 12, 15
Continue cefazolin as it is the appropriate first-line therapy for MSSA bacteremia, with a recommended duration of 2-3 weeks for uncomplicated bacteremia with adequate source control 9
Longer therapy (4-6 weeks) may be needed for complicated bacteremia with high-risk features, as determined by the IDSA guidelines 12

Management of Persistent MSSA Bacteremia on Cefazolin

Immediate Actions Required

The Infectious Diseases Society of America recommends obtaining repeat blood cultures immediately to confirm ongoing bacteremia in patients with persistent MSSA bacteremia on cefazolin, and performing a thorough physical examination to identify potential sources of infection, such as drainable abscesses or fluid collections, signs of endocarditis, joint swelling or warmth suggesting septic arthritis, vertebral tenderness suggesting osteomyelitis or epidural abscess, and intravascular catheter sites for signs of infection 16, 17
The American College of Cardiology recommends obtaining transesophageal echocardiography (TEE) immediately if not already done, as it is superior to transthoracic echocardiography (TTE) for detecting endocarditis in patients with persistent MSSA bacteremia on cefazolin 17, 18

Source Control - The Critical Priority

The Infectious Diseases Society of America recommends removing any temporary intravascular catheters immediately and surgically draining any identified abscesses or fluid collections in patients with persistent MSSA bacteremia on cefazolin 16, 19
The Centers for Disease Control and Prevention recommend evaluating for and draining septic thrombophlebitis in patients with persistent MSSA bacteremia on cefazolin 16

Antibiotic Management

The Infectious Diseases Society of America states that adding rifampin or gentamicin to beta-lactam therapy for MSSA bacteremia is NOT recommended and does not improve outcomes, with a strength of evidence classified as strong 17, 18
The American College of Cardiology recommends considering combination therapy with daptomycin + ceftaroline only if persistent bacteremia continues beyond 5-7 days despite adequate source control, with a strength of evidence classified as moderate 16

Risk Stratification and Duration

The Infectious Diseases Society of America classifies patients with positive blood cultures at day 3 as having complicated bacteremia, requiring a minimum treatment duration of 4-6 weeks, with a strength of evidence classified as strong 17, 18
The American College of Cardiology recommends that the duration of treatment depend on time to blood culture clearance, presence of metastatic foci, and presence of endocarditis, with a strength of evidence classified as moderate 16, 17

Monitoring Strategy

The Infectious Diseases Society of America recommends obtaining blood cultures daily until clearance is documented, and being aware of the "skip phenomenon" where cultures may be intermittently negative before complete clearance, with a strength of evidence classified as strong 16, 17, 18
The American College of Cardiology recommends considering advanced imaging, such as CT chest/abdomen/pelvis, to evaluate for occult abscesses in patients with persistent MSSA bacteremia on cefazolin, with a strength of evidence classified as moderate 16
The European Society of Clinical Microbiology and Infectious Diseases recommends considering PET/CT for identifying deep-seated foci, though this remains investigational, with a strength of evidence classified as low 20

Management of Persistent MSSA Bacteremia with Uncontrolled Focus

Introduction to MSSA Bacteremia Management

The American Heart Association/American College of Cardiology guidelines establish an indication for early surgery (during the initial hospitalization) in patients with persistent bacteremia or fever lasting more than 5-7 days despite appropriate antimicrobial therapy 21, 22, 23
The priority is control of the infection focus through urgent surgical intervention, not changing antibiotics 21

Diagnostic Approach

Transesophageal echocardiogram (TEE) is recommended in cases of persistent S. aureus bacteremia, as it has a 30-40% probability of endocarditis 21, 22
TEE is superior to transthoracic echocardiogram for detecting vegetations and abscesses 21

Antibiotic Management

The Infectious Diseases Society of America recommends discontinuing ertapenem immediately, as it is not an appropriate antibiotic for MSSA 24, 25
Cefazolina 2g IV every 8 hours is the correct treatment, and the addition of gentamicina is not recommended (Class III) 25

Surgical Intervention

Surgery improves mortality in patients with abscesses and persistent sepsis, as these patients have a high risk of multi-organ failure 21

Duration of Treatment

For complicated bacteremia (positive blood cultures >72 hours), a minimum of 4-6 weeks of therapy is recommended 21, 25
If endocarditis is confirmed, 6 weeks of therapy is recommended 21, 25

Complicated Staphylococcus aureus Bacteremia Management

Patient Selection and Risk Factors

The Infectious Diseases Society of America (IDSA) guidelines recommend that patients with S. aureus bacteremia who are hemodialysis-dependent have significantly higher risk of hematogenous complications and require longer courses of therapy 26
Hemodialysis dependence is explicitly identified as a high-risk feature requiring longer therapy, and the presence of a retained foreign body, such as a dialysis fistula, increases the risk of hematogenous complications 26
Infections of primary arteriovenous fistulas should be treated for 6 weeks, analogous to subacute bacterial endocarditis, according to the 2009 IDSA catheter-related infection guidelines 27

Duration of Therapy

For complicated bacteremia with positive blood cultures and inadequate source control, the minimum duration is 4-6 weeks of IV therapy from the date of first negative blood culture, as recommended by the IDSA guidelines 28
The IDSA guidelines specify that uncomplicated bacteremia requires all of the following: hospital-acquired infection, blood cultures clear in <48 hours, defervescence within 72 hours, no prosthetic devices or retained foreign bodies, negative TEE, no metastatic infection, and complete source control achieved 28

Diagnostic Evaluation

Transesophageal echocardiography (TEE) should be strongly considered in patients with high-risk features, such as hemodialysis dependence, despite a negative transthoracic echocardiogram (TTE), as TEE is more sensitive for detecting endocarditis 28